Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: A children's oncology group study (POG 8764)

Michael J. Joyce, Bradley H Pollock, Meenakshi Devidas, George R. Buchanan, Bruce Camitta

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Children with acute lymphocytic leukemia who fail to enter remission have a poor prognosis. In a previous study, 9 of 14 children with induction failure entered remission after teniposide (VM26) plus cytosine arabinoside (Ara-C). We attempted to confirm these results. Twenty children received teniposide (200 mg/m/day IV) for 3 days and cytosine arabinoside (100 mg/m/day continuous IV infusion) for 7 days. There were 3 complete and 3 partial responses. Two additional patients achieved a complete response after a second, shorter course of the same agents. Although VM26 plus Ara-C is an active combination for treatment of acute lymphocytic leukemia induction failure, it does not appear as effective as in the initial report. Better treatments for this problem are needed.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume35
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Keywords

  • acute lymphoblastic leukemia
  • chemotherapy
  • induction failure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: A children's oncology group study (POG 8764)'. Together they form a unique fingerprint.

  • Cite this